Transfermoral aortic valve implantation using self-expanding New Valve Technology (NVT) Allegra bioprosthesis: A pilot prospective study by Jagielak, Dariusz et al.
Address for correspondence: Dariusz Jagielak, MD, PhD, Department of Cardiac and Vascular Surgery, ul. Dębinki 7,  
80–241 Gdańsk, Poland, tel: +48 509487577, e-mail: darjag@gumed.edu.pl 
Received: 25.07.2018 Accepted: 23.01.2019
Transfermoral aortic valve implantation using  
self-expanding New Valve Technology (NVT)  
Allegra bioprosthesis: A pilot prospective study 
Dariusz Jagielak1, Aleksandra Stanska1, Andrzej Klapkowski1, Maciej Brzezinski1,  
Maciej Kowalik1, Dariusz Ciecwierz2, Milosz Jaguszewski2, Marcin Fijalkowski2
1Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland 
21st Department of Cardiology, Medical University of Gdansk, Poland
This paper was guest edited by Prof. Wojciech Wojakowski
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has become a standard therapeutic 
option for patients with severe aortic stenosis (AS) at high cardiac surgical risk. The aim of the NAU-
TILUS study was to investigate the safety and performance of the New Valve Technology (NVT) Allegra 
bioprosthesis in high-risk patients undergoing TAVI.
Methods: Twenty seven patients with severe, symptomatic AS at high surgical risk were prospectively 
enrolled, who underwent treatment using the novel self-expanding NVT Allegra bioprosthesis via trans-
femoral approach (TF-TAVI). The primary end-point was all-cause mortality at 30 days. 
Results: Patients were elderly (83 years, range 75–89 years), and predominantly female (70.4%, n = 19).  
All patients were deemed to be at high surgical risk, with a mean logistic EuroSCORE of 12.4% (range, 
2.8–31.8%). The bioprosthesis was successfully implanted in 96% of the cases (n = 25). The echocardio-
graphic assessment confirmed good hemodynamic profile after implantation of the NVT Allegra biopros-
thesis. Complications included cardiac tamponade (4%, n = 1) and the need for permanent pacemaker 
implantation (8%, n = 2). The analysis of procedural aspects showed a short learning effect related to 
the precise placement of the valve. A significant improvement in clinical symptoms were observed, and 
no patients died in-hospital or within 30 days of post-discharge observation.
Conclusions: This prospective observation shows that the NVT Allegra bioprosthesis was associated 
with a satisfactory safety profile and a remarkable hemodynamic performance after implantation.  
(Cardiol J XXXX; XX, X: xx–xx)
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implantation
Introduction
Transcatheter aortic valve implantation (TAVI) 
has evolved from a challenging and hazardous pro-
cedure to a minimally invasive, safe, and predict-
able treatment strategy. It has become a standard 
treatment for intermediate and high-risk patients 
with severe aortic stenosis (AS) [1]. Since 2002, 
when the first TAVI was performed [2], a large 
number of studies have proven its clinical utility 
and low rates of procedure-related complications 
[3]. Currently, in some countries, the annual rate of 
TAVIs surpassed the surgical replacement proce-
dure [4]. Even though there are many Conformité 
Européenne (CE) marked devices available, there 
is still a strong need for further technological im-
provement and new valve design. In spite of the 
procedural success, undesirable, adverse events 
related to the TAVI procedure or TAVI system 
are still reported in up to 4% of cases [5–10]. Im-
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provement of technology may have the potential 
to minimize the complication rate [11]. 
The New Valve Technology (NVT) Allegra sys-
tem is a novel self-expanding TAVI device designed 
to overcome some limitations of the first-genera-
tion systems, including malpositioning, paravalvu-
lar leakage (PVL), hemodynamic compromise, and 
necessity for pacemaker implantation. The valve 
is implanted in a three-step deployment process 
that ensures accurate final positioning (Fig. 1). 
The first-in-human experience showed a high rate 
of procedural success, satisfactory hemodynamic 
results, and clinical symptom improvement [12].
The purpose of this study was to assess the 
safety and performance of the novel NVT Allegra 
self-expanding aortic prosthesis using a transfemo-
ral approach. The study provides 30-day outcomes 
in a high-risk patient setting, treated in a well-
experienced TAVI center.
Methods
Study overview and patient population 
NAUTILUS (NVT trAnsfemoral mUlticentric 
aorTIc valve pivotaL stUdy for Safety and effective-
ness) was a single-arm clinical study conducted at 
8 centers in 3 countries (Switzerland, Poland, and 
Brazil), designed to assess the safety and perfor-
mance of the NVT Allegra TAVI System (NVT, 
GmbH, Hechingen, Germany). 
Herein, is presented the largest single-center 
experience with the novel NVT Allegra system 
implanted in 26 patients accepted by the Heart 
Team to undergo transfemoral transcatheter aortic 
valve implantation (TF-TAVI). All patients suf-
fered from severe, symptomatic AS and met the 
NAUTILUS eligibility criteria. The main inclusion 
criteria were: 1) age ≥ 75 years; 2) symptomatic 
(New York Heart Association [NYHA] class II or 
greater) severe degenerative native AS (mean 
transvalvular pressure gradient > 40 mmHg and/
or aortic jet velocity > 4.0 m/s and/or aortic valve 
area of < 1.0 cm² [or aortic valve area index ≤ 
0.6 cm2/m2]); 3) high risk for surgical aortic valve 
replacement with a logistic EuroSCORE ≥ 20%, 
or documented agreement of the Heart Team that 
the patient is at high risk for surgery due to frailty 
and/or coexisting comorbidities.
Amongst others, the protocol defined exclu-
sion criteria comprised: 1) unicuspid or bicuspid 
valve disease; 2) non-calcified aortic valve disease; 
3) mixed valve disease with predominant aortic 
regurgitation greater than 3+ or with associated 
severe (greater than 3+) mitral regurgitation; 
4) aortic annulus size < 19 mm or > 29 mm; 5) 
type of femoral access, or any other anatomical 
conditions that prevented safe placement of an 18 
French introducer sheath and manipulation of the 
TAVI system (e.g. severe femoral-iliac obstructive 
calcification or tortuosity) [13]. 
All patients were followed-up for 30 days. 
Written informed consent was obtained from each 
participant. The study was approved by the local 
ethics committee and the competent authority.
NVT Allegra system and the TAVI  
implantation protocol
The NVT Allegra transcatheter heart valve 
(Fig. 1) is a self-expanding device, designed to 
avoid hemodynamic compromise and to facilitate 
correct positioning during the subsequent steps 
of implantation. The valve consists of a nitinol 
stent frame and bovine pericardium (annular skirt 
and leaflets). The stent frame has a closed cell, 
diamond-shaped configuration. The variable cell 
size distribution allows for better coronary perfu-
sion and easier access for any further percutane-
ous coronary interventions. Six radiopaque gold 
markers are incorporated into the stent frame. 
They indicate the distal part of the semilunar valve 
to facilitate correct valve positioning. The 12-mm 
bovine pericardial sealing skirt reduces the risk of 
significant PVL. The NVT Allegra valve is available 
in 3 sizes (23, 27 and 31 mm), with a frame height of 
37.3, 41.3, and 43.0 mm, respectively, (Table 1) cover-
ing aortic annulus diameter sizes from 19 to 29 mm.
The delivery system has an 18 French cartridge 
and a 15 French catheter shaft. The grip uses a 
Squeeze-to-Release® mechanism, which prevents 
rotation during a stepwisely performed implanta-
T-shaped connecting bars
Radiopaque gold markers
Sealing zone
Figure 1. Design of the Allegra valve.
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tion. The prosthesis is released in a three-step 
deployment mechanism. The novel implantation 
technology (PermaFlow®; New Valve Technology) 
facilitates positioning of the Allegra valve and pre-
vents interference with the left ventricular outflow 
tract. In the first step of the implantation, the middle 
part of the valve is released, while both ends of the 
device are still captured (Fig. 2). During the second 
step, the bottom of the valve is released (Fig. 3). The 
operator can assess valve position, patency of the 
coronaries, hemodynamic functions, and paravalvu-
lar regurgitation. The process can be re-started till 
this step, and the valve can thus be retrieved. In the 
third step, when the operator confirms the position 
of the prosthesis, the safety locker is released for 
final deployment of the NVT Allegra valve.
All procedures were performed via the open 
transfemoral approach for TAVI (TF-TAVI) under 
local or general anaesthesia. According to the 
protocol, pre-dilatation before valve implantation 
was mandatory.
Data management and statistical analysis
The data for the clinical trial was collected pro-
spectively during hospitalization (baseline and dis-
charge) and after 30 days in an outpatient setting by 
using a dedicated electronic case report form. Each 
patient underwent transthoracic echocardiography 
assessment at least three times — before the im-
plantation, after the procedure and/or at discharge 
and after 1 month. Hemodynamic prosthesis per-
formance assessment estimation included maximal 
velocity, mean pressure gradient, effective orifice 
area, and presence and grade of PVL. Results were 
presented as numbers of patients (percentages) or 
means, where applicable. Statistical analysis was 
performed using STATISTICA 12.0 PL (StatSoft, 
Krakow, Poland). 
Results
Twenty-seven patients were considered eli-
gible for the treatment and signed the informed 
consent. One patient underwent isolated balloon 
valvuloplasty of the native aortic valve due to un-
expected anatomical conditions; massive, bulky 
asymmetric calcification. Therefore, 26 patients 
Table 1. Specifications of New Valve Technology 
(NVT) Allegra transcatheter valve.
NVT 23 NVT 27 NVT 31
Frame height [mm] 37.3 41.3 43.0
Inflow diameter [mm] 23.8 27.4 31.0
Outflow diameter [mm] 20.8 24.0 24.0
Tissue annulus  
diameter [mm]
19–22 22–25 25–29
Figure 2. The Allegra valve positioning.
Figure 3. Releasing of the bottom of the valve.
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underwent attempted implantation of the NVT 
Allegra valve.
The patient population was elderly with a 
mean age of 83 years (range, 75–89 years), 70.4% 
were female, and the mean logistic EuroSCORE 
was 12.4% (range, 2.8–31.8%). Patient character-
istics and parameters at baseline are presented in 
Table 2. 
The implantation of a single functioning NVT 
bioprosthesis in the correct annular position was 
successfully completed in 25 patients. Due to the 
dislocation of the prosthesis into the left ventri-
cle, 1 patient required open-heart aortic valve 
replacement. Flow chart of the study is presented 
(Fig. 4). The dislocation of the valve was caused 
by the combination of a relatively low degree of 
calcification of the annulus, and disconnection of 
the prosthesis from the delivery system. 
Most events were considered as expected and 
documented in the case report form (Table 3). Two 
patients could not attend the clinic for a follow-up 
visit at 30 days and clinical data were collected by 
the phone. No patient died within the period of 30 
days (Table 4). 
The echocardiographic assessment immedi-
ately after valve implantation and before discharge 
showed excellent hemodynamic performance, 
which was maintained at 30 days (Table 5). At 30 
days, the majority (84%) had only mild or less 
residual aortic regurgitation, while 16% moder-
ate and 0% severe aortic regurgitation was noted 
(Table 6). 
Discussion
This is the largest single-center study of the 
novel transcatheter self-expanding NVT Allegra 
bioprosthesis transfemoral system. The main 
purpose of the NAUTILUS study was to assess 
safety and performance of the NVT Allegra valve. 
The new valve had a favorable post-deployment 
hemodynamic profile, with low post-procedural 
transvalvular gradients. No cardiac death or cere-
brovascular incidents, as well as a very low perma-
nent pacemaker implantation rate was recorded at 
30 days. These results suggest that the novel valve 
has a good safety and efficacy profile and could be 
used in patients with severe symptomatic AS. 
Given the dynamic development of the pro-
cedure and different product refinements, the 
field of transcatheter heart valve systems is cur-
rently highly competitive, with a wide spectrum 
of various CE-marked devices. However, TAVI is 
still associated with a risk of severe complications, 
which may occur in up to 5% of procedures [1]. 
The contemporary TAVI system design should 
provide easy positioning, and an option to retrieve 
Table 2. Preoperative characteristics and param-
eters (n = 27).
Age [years] 83 (75–89)
Gender:
Male 8 (29.6%)
Female 19 (70.4%)
Logistic EuroSCORE [%] 12.4 (2.8–31.8)
Hypertension 22 (81.5%)
Diabetes mellitus 14 (51.8%)
COPD 5 (18.5%)
Coronary artery stenosis (> 50%) 2 (7.4%)
Previous myocardial infarction 7 (25.9%)
Previous coronary surgery 4 (14.8%)
Previous coronary angioplasty 12 (44.4%)
Previous stroke or TIA 1 (3.7%)
Creatinine clearance (< 60 mL/min) 7 (25.9%)
NYHA:
I –
II 3 (11.1%)
III 23 (85.2%)
IV 1 (3.7%)
Conduction disorders  
(LBBB, RBBB, AVB)
2 (7.4%)
Pre-existing permanent pacemaker 3 (11.1%) 
Aortic valve insufficiency (≥ mild) 11 (40.7%)
Mitral valve insufficiency (≥ mild) 18 (66.7%)
AVB — atrio-ventricular block; COPD — chronic obstructive pulmo-
nary disease; LBBB — left bundle branch block; NYHA — New York 
Heart Association functional class; RBBB — right bundle branch 
block; TIA — transient ischemic attack
Figure 4. Flow chart of the study; BAV — balloon aortic 
valvuloplasty.
Patients enrolled to the study
n = 27 
Exclusion 
(BAV performed)
n = 1
Implantantion 
of the valve
n = 26
Dislocation 
of the valve 
n = 1
Succesful implantation 
and further follow-up 
n = 25
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the device when the position of the valve is com-
promised. A reduced rate of complications related 
to the malposition of the prosthesis such as PVL, 
pacemaker implantation or overlie of coronary ostia 
is essential for improving long-term results. 
In this study, a high rate of procedural success 
was demonstrated with the Allegra NVT biopros-
thesis (96%). One of the greatest advantages of this 
new system is the ability to reposition and retrieve 
the device in cases of malposition or a suboptimal 
result. In the present cohort, the device had to be 
retrieved in 2 patients. The retrieving maneuvers 
and second deployment were easily controlled 
without complications. The Allegra system has 
features allowing for very precise positioning. The 
presence of radiopaque markers in the delivery 
system as well as at the transition between the 
annular skirt and the bottom of the leaflets, mark-
edly facilitates the procedure by enabling direct 
and clear visualization of the optimal implantation 
height and limits of the sealing skirt. 
The overall risk of permanent atrio-ventricular 
conduction disturbances following TAVI proce-
dures varies, but remains around 17% [14]. In 
comparison to balloon expandable valves, the self-
expandable (nitinol-based) TAVI valve prostheses 
have a slightly higher rate of postprocedural atrio-
ventricular conduction block, requiring pacemaker 
implantation (28%) [15, 16]. In this study, only 8% 
of patients required pacemaker implantation, and 
incomparison to other self-expandable valve pros-
theses, this is a very promising result. This may be 
related to a high valve implantation facilitated by 
refined deployment technology and valve design.
Table 3. Procedural characteristics (n = 27).
Procedural success 25 (92.6%)
(one prosthesis implanted)
Failed study valve implantation: 2 (7.4%)
Valve-in-valve 0 (0%)
Conversion to other TAVI 0 (0%)
Conversion to surgical AVR 1 (3.7%)
Unexpected anatomical conditions 1 (3.7%)
Attempted valve retrieval:
Successful retrieval 2 (7.4%)
Failed retrieval 0 (0%)
Fluoroscopy time [min] 17.6 (7–60)
Volume of contrast [mL] 107 (60–290)
Valve size (n = 27):
23 mm 0 (0%)
27 mm 15 (55.6%)
31 mm 11 (40.7%)
Need for post-dilatation 0 (0%)
AVR — aortic valve replacement; TAVI — transcatheter aortic valve 
implantation
Table 4. Prevalence of clinical outcomes and  
adverse events (n = 25).
All-cause mortality 0 (0%)
Permanent pacemaker implantation  
due to atrio-ventricular block
2 (8%)
Sepsis 1 (4%)
Any stroke 0 (0%)
Pericardium drainage due to late  
cardiac tamponade 
1 (4%)
Renal failure 0 (0%)
Respiratory failure 1 (4%)
Major vascular complication 0 (0%)
Minor vascular complication 0 (0%)
Acute myocardial infarction 0 (0%)
Minor bleeding (sheath failure) 1 (4%)
Table 5. Echocardiographic aortic valve function from baseline until 30 days of patients successfully 
treated with the study prosthesis.
Baseline (n = 27) Discharge (n = 25) 30-days (n = 23)
Peak gradient [mmHg] 87 (58–138) 16.9 (8–42) 15.9 (8–27)
Mean gradient [mmHg] 56.8 (35–91) 9.4 (4–21) 9 (4–16)
Peak aortic velocity [m/s] 4.6 (4–6) 2 (1–3) 2 (1–3)
Effective orifice area [cm2] 0.63 (0–1) 1.4 (1–2) 1.5 (1–2)
Table 6. The prevalence of paravalvular leakage 
(PVL) on discharge day and 30-days follow-up (FU).
PVL Discharge  
(n = 25)
30-days FU  
(n = 23)
None 3 (12%) 3 (13%)
Mild 18 (72%) 16 (69.6%)
Moderate 4 (16%) 4 (17,4%)
Severe 0 (0%) 0 (0%)
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The releasing mechanism of the Allegra allows 
for a stable and stepwise delivery of the valve, 
which starts to function early in the deployment 
process, preventing hemodynamic collapse. 
Despite the supra-annular design, the Allegra 
valve has a reduced frame height to facilitate ma-
nipulation and deployment. Short TAVI systems 
with supra-annular construction are advantageous 
for the percutaneous treatment of degenerated 
surgical bioprostheses [11, 12]. However, patients 
with non-native aortic valve stenosis were ex-
cluded from the study. 
The durability of transcatheter aortic valve bi-
oprostheses still remains unknown. The first TAVI 
procedures were performed in the early 2000s, 
and the age and clinical profile of that early group 
of patients make a clear evaluation of TAVI dura-
bility very difficult. Patients with either serious 
co-morbidities and/or are elderly have restricted 
prediction of life expectancy. Transferring TAVI 
to lower-risk, younger patients with longer life 
expectancy increases the requirements regarding 
freedom from structural valve deterioration. Ran-
domized trials in this group of patients are already 
under way [13]. The novel Allegra system tested in 
the present study incorporates a feature that aims 
to improve a long-term bioprosthesis functional 
life. The upper portion of its nitinol frame, to which 
the commissures of the valve leaflets are attached, 
has increased compliance and is able to partially 
flex, accommodating the forces generated across 
the cardiac cycle, reducing the mechanical stress on 
the leaflets. Reduction of the stress on the biologi-
cal part of the valve (i.e. pericardial leaflets) would 
result in enhanced valve durability. Obviously, such 
an effect cannot be evaluated in the 30-day results 
presented in the current study and requires longer 
observation periods.
Moderate-aortic regurgitation occurred in 
16% of patients at 30 days, which is proportional to 
other self-expandable-valve-studies [4]. Moreover, 
it is noteworthy that there was no severe PVL in 
the present setting. Altogether, it is not possible 
to rule out whether these events are inherent to 
valve design or complications that can be mini-
mized as experience with the prosthesis grows 
and the learning curve levels out. Nevertheless, 
the results presented are promising, particularly 
when compared to other TAVI devices in similar 
clinical scenarios. 
Stroke and other cerebrovascular events (CVE) 
remain common complications following TAVI, rang-
ing between 1.5% and 4% [17–19]. The incidence 
of CVEs is highly related to a higher mortality rate 
and longer hospital stay [19, 20]. In the current 
subset, not a single procedure was complicated with 
cerebrovascular incidents in the 30-day follow-up 
period. Compared to other studies, this is an out-
standing result, confirming safety of the procedure 
and prosthesis itself. It requires further observation, 
nevertheless, the first month is usually the most 
vulnerable period for CVE incidence.
Surgical cut-down was used as vascular access 
in all cases. There were no vascular complications. 
The valve has good transition and controllability, 
but estimation of iliofemoral anatomy is crucial in 
prevention of vascular events.   
The Allegra system is intuitive and easy to 
use. The learning curve regarding the precision 
of placement of the device is short.
Limitations of the study
The present study has some important short-
comings. It is a single-arm study of relatively small 
sample size, which per se precludes any in-depth 
comparison against a control group or detailed 
analyses related to uncommonly-occurring events. 
Furthermore, the evaluation was focused on the 
short-term safety and effectiveness, and no infer-
ences can be drawn regarding long-term outcomes 
after implantation of the device. 
Conclusions
This prospective study shows a satisfactory 
safety and performance profile of NVT Allegra 
bioprosthesis. This novel valve prosthesis has an 
excellent hemodynamic performance and low rate 
of pacemaker implantations. The analysis of pro-
cedural aspects showed a favorable learning curve 
related to precision of placement of the prosthesis.
References
1. Aldalati O, MacCarthy P, Dworakowski R. Trans-catheter aortic 
valve implantation: Contemporary practice and the future. Car-
diol J. 2017; 24(2): 206–215, doi: 10.5603/CJ.a2017.0022, indexed 
in Pubmed: 28248406.
2. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous tran-
scatheter implantation of an aortic valve prosthesis for calcific 
aortic stenosis: first human case description. Circulation. 2002; 
106(24): 3006–3008, indexed in Pubmed: 12473543.
3. Giordana F, D’Ascenzo F, Nijhoff F, et al. Meta-analysis of predic-
tors of all-cause mortality after transcatheter aortic valve im-
plantation. Am J Cardiol. 2014; 114(9): 1447–1455, doi: 10.1016/j.
amjcard.2014.07.081, indexed in Pubmed: 25217456.
4. Eggebrecht H, Mehta RH. Transcatheter aortic valve implanta-
tion (TAVI) in Germany 2008-2014: on its way to standard ther-
apy for aortic valve stenosis in the elderly? EuroIntervention. 
2016; 11(9): 1029–1033, doi:  10.4244/EIJY15M09_11, indexed 
in Pubmed: 26384006.
6 www.cardiologyjournal.org
Cardiology Journal XXXX, Vol. XX, No. X
5. Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in 
patients undergoing transcatheter aortic valve replacement: inci-
dence and predictors of advanced heart failure and sudden cardiac 
death. J Am Coll Cardiol. 2015; 65(5): 437–448, doi: 10.1016/j.
jacc.2014.11.027, indexed in Pubmed: 25660921.
6. Ribeiro HB, Nombela-Franco L, Muñoz-García AJ, et al. Predic-
tors and impact of myocardial injury after transcatheter aortic 
valve replacement: a multicenter registry. J Am Coll Cardiol. 
2015; 66(19): 2075–2088, doi:  10.1016/j.jacc.2015.08.881, in-
dexed in Pubmed: 26541917.
7. Gensas CS, Caixeta A, Siqueira D, et al. Predictors of permanent 
pacemaker requirement after transcatheter aortic valve implantation: 
insights from a Brazilian registry. Int J Cardiol. 2014; 175(2): 248–252, 
doi: 10.1016/j.ijcard.2014.05.020, indexed in Pubmed: 24880480.
8. Wenaweser P, Stortecky S, Heg D, et al. Short-term clinical 
outcomes among patients undergoing transcatheter aortic valve 
implantation in Switzerland: the Swiss TAVI registry. EuroIn-
tervention. 2014; 10(8): 982–989, doi:  10.4244/EIJV10I8A166, 
indexed in Pubmed: 24694729.
9. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, man-
agement, and clinical outcomes of coronary obstruction following 
transcatheter aortic valve implantation: insights from a large 
multicenter registry. J Am Coll Cardiol. 2013; 62(17): 1552–1562, 
doi: 10.1016/j.jacc.2013.07.040, indexed in Pubmed: 23954337.
10. Athappan G, Patvardhan E, Tuzcu EM, et al. Incidence, pre-
dictors, and outcomes of aortic regurgitation after transcath-
eter aortic valve replacement: meta-analysis and systematic 
review of literature. J Am Coll Cardiol. 2013; 61(15): 1585–1595, 
doi: 10.1016/j.jacc.2013.01.047, indexed in Pubmed: 23500308.
11. Tchetche D, Van Mieghem NM. New-generation TAVI devices: 
description and specifications. EuroIntervention. 2014; 10 Suppl 
U: U90–U9U100, doi: 10.4244/EIJV10SUA13, indexed in Pub-
med: 25256338.
12. Wenaweser P, Stortecky S, Schütz T, et al. Transcatheter aortic 
valve implantation with the NVT Allegra transcatheter heart valve 
system: first-in-human experience with a novel self-expanding 
transcatheter heart valve. EuroIntervention. 2016; 12(1): 71–77, 
doi: 10.4244/EIJV12I1A13, indexed in Pubmed: 27173865.
13. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint def-
initions for Transcatheter Aortic Valve Implantation clinical tri-
als: a consensus report from the Valve Academic Research Con-
sortium. J Am Coll Cardiol. 2011; 57(3): 253–269, doi: 10.1016/j.
jacc.2010.12.005, indexed in Pubmed: 21216553.
14. Siontis GCM, Jüni P, Pilgrim T, et al. Predictors of permanent 
pacemaker implantation in patients with severe aortic stenosis 
undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014; 
64(2): 129–140, doi: 10.1016/j.jacc.2014.04.033, indexed in Pub-
med: 25011716.
15. Hayashida K, Morice MC, Chevalier B, et al. Sex-related differ-
ences in clinical presentation and outcome of transcatheter aortic 
valve implantation for severe aortic stenosis. J Am Coll Cardiol. 
2012; 59(6): 566–571, doi: 10.1016/j.jacc.2011.10.877, indexed in 
Pubmed: 22300690.
16. Khawaja MZ, Rajani R, Cook A, et al. Permanent pacemaker in-
sertion after CoreValve transcatheter aortic valve implantation: 
incidence and contributing factors (the UK CoreValve Collabora-
tive). Circulation. 2011; 123(9): 951–960, doi: 10.1161/CIRCU-
LATIONAHA.109.927152, indexed in Pubmed: 21339482.
17. Eggebrecht H, Schmermund A, Voigtländer T, et al. Risk of 
stroke after transcatheter aortic valve implantation (TAVI): 
a meta-analysis of 10,037 published patients. EuroIntervention. 
2012; 8(1): 129–138, doi: 10.4244/EIJV8I1A20, indexed in Pub-
med: 22391581.
18. Chieffo A, Buchanan GL, Van Mieghem NM, et al. Transcatheter 
aortic valve implantation with the Edwards SAPIEN versus the 
Medtronic CoreValve Revalving system devices: a multicenter 
collaborative study: the PRAGMATIC Plus Initiative (Pooled-
RotterdAm-Milano-Toulouse In Collaboration). J Am Coll Cardi-
ol. 2013; 61(8): 830–836, doi: 10.1016/j.jacc.2012.11.050, indexed 
in Pubmed: 23333140.
19. Tchetche D, Farah B, Misuraca L, et al. Cerebrovascular events 
post-transcatheter aortic valve replacement in a large cohort 
of patients: a FRANCE-2 registry substudy. JACC Cardiovasc 
Interv. 2014; 7(10): 1138–1145, doi: 10.1016/j.jcin.2014.04.018, 
indexed in Pubmed: 25240554.
20. Stortecky S, Windecker S, Pilgrim T, et al. Cerebrovascular 
accidents complicating transcatheter aortic valve implantation: 
frequency, timing and impact on outcomes. EuroIntervention. 
2012; 8(1): 62–70, doi: 10.4244/EIJV8I1A11, indexed in Pubmed: 
22580250.
www.cardiologyjournal.org 7
Dariusz Jagielak et al., Short-term results after NVT Allegra bioprosthesis implantation
